More About Jay
Jay Rughani is an investing partner at Andreessen Horowitz where he specializes in healthcare technology, with a focus on AI & data products. He is inspired by entrepreneurs using software to accelerate clinical research, enable better care delivery, and increase affordability for patients. Jay helped to lead a16z’s investments in and is partnered with numerous ambitious companies, including Biodock, Freenome, Inductive, Komodo, Orchestra, Pearl, Thatch, Thyme, Topography, Turquoise, and Valar.
Prior to joining a16z in 2018, Jay was an early team member at Flatiron Health (acquired by Roche for ~$2bn). There, he helped to build some of the company’s first healthcare data & analytics products. He later led numerous commercial partnerships with large biopharma companies, smaller biotechs, and other healthcare organizations. Before Flatiron, he consulted for large healthcare and technology companies around the world at Deloitte, worked at a seed-stage multi-sided network startup called Dealermatch (acquired by Cox Enterprises), and co-founded an unsuccessful startup with his college roommate.
Jay graduated from Emory University with a degree in Mathematics & Economics and grew up mostly in Palm Harbor, FL, apart from a 3 year stint in boarding school in London, UK (not Hogwarts, regrettably).
Featured Content
-
Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.
-
The world is amidst an AI-driven industrial revolution. Whether we let it improve the health of Americans is up to how we regulate it. There is no sector where AI can drive more immediate, life-saving impact than in biotechnology and healthcare.
-
How can digital health founders successfully implement channel partnerships to accelerate the distribution of their products and services? When should they use them? How should they use them? We spoke with the founders of Omada, Ginger, and Cedar, each of which have successfully utilized channel partnerships, and surveyed 36 other digital health startups to analyze the state of channel partnerships in the market today.
-
Today’s episode is with Sean Duffy, cofounder and CEO of Omada Health. He is joined by a16z Bio + Health general partner Julie Yoo and investment partner Jay Rughani.
-
The public market situation for healthtech can seem pretty depressing. Recently IPOed healthtech stocks are underperforming the broader market, with some falling 95%+ from their IPO—meanwhile, more traditional companie...
